August 11, 2016 11:14 AM EDT
R&D

Pro­tag­o­nist’s IPO op­tion de­liv­ers a $90M pay­off for ear­ly-stage pep­tide work

John Carroll

Editor & Founder

A year ago, when I was talk­ing about Pro­tag­o­nist Ther­a­peu­tics’ fu­ture with Di­nesh Pa­tel, the CEO fo­cused in on “op­tion­al­i­ty.” There could be deals, there …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times